We are live on ! Find out more
ProShare Advisors

ProShare Advisors Portfolio holdings

AUM $67.5B
1-Year Est. Return 28.09%
This Fund
S&P 500
This Quarter Est. Return
+7.12%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$14.4B
AUM Growth
+$3.53B
Cap. Flow
+$2.81B
Cap. Flow %
19.5%
Top 10 Hldgs %
18.41%
Holding
1,820
New
468
Increased
1,221
Reduced
109
Closed
21

Sector Composition

Rank Sector Weight
1 Technology 16.64%
2 Financials 14.34%
3 Healthcare 13.98%
4 Consumer Staples 10.45%
5 Industrials 10.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HMHC
1701
DELISTED
Houghton Mifflin Harcourt Company
HMHC
$143K ﹤0.01%
+15,357
New +$153K
PRKS icon
1702
United Parks & Resorts
PRKS
$2.13B
$140K ﹤0.01%
+10,293
New +$128K
INFN
1703
DELISTED
Infinera Corporation Common Stock
INFN
$139K ﹤0.01%
+21,903
New +$167K
SXC icon
1704
SunCoke Energy
SXC
$710M
$138K ﹤0.01%
+11,519
New +$124K
FBRX icon
1705
Forte Biosciences
FBRX
$1B
$136K ﹤0.01%
+36
New +$144K
IMUX icon
1706
Immunic
IMUX
$207M
$135K ﹤0.01%
+57
New +$126K
KTOS icon
1707
Kratos Defense & Security Solutions
KTOS
$8.63B
$135K ﹤0.01%
+12,711
New +$145K
AROC icon
1708
Archrock
AROC
$6.51B
$132K ﹤0.01%
+12,533
New +$136K
QUOT
1709
DELISTED
Quotient Technology Inc
QUOT
$132K ﹤0.01%
+11,231
New +$156K
AUPH icon
1710
Aurinia Pharmaceuticals
AUPH
$2.05B
$130K ﹤0.01%
+28,783
New +$160K
CRVS icon
1711
Corvus Pharmaceuticals
CRVS
$1.25B
$130K ﹤0.01%
+12,587
New +$161K
SNDX icon
1712
Syndax Pharmaceuticals
SNDX
$2.02B
$130K ﹤0.01%
+14,887
New +$147K
NPKI
1713
NPK International
NPKI
$1.21B
$130K ﹤0.01%
+15,110
New +$137K
TLGT
1714
DELISTED
Teligent, Inc
TLGT
$127K ﹤0.01%
3,487
+197
+6% +$9.42K
NSTG
1715
DELISTED
NanoString Technologies, Inc.
NSTG
$125K ﹤0.01%
16,734
+1,124
+7% +$10.7K
GPRO icon
1716
GoPro
GPRO
$114M
$123K ﹤0.01%
+16,198
New +$144K
FOMX
1717
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$121K ﹤0.01%
20,166
-914
-4% -$5.5K
CASC
1718
DELISTED
Cascadian Therapeutics, Inc.
CASC
$120K ﹤0.01%
+32,469
New +$133K
FMSA
1719
DELISTED
Fairmount Santrol Holdings Inc.
FMSA
$120K ﹤0.01%
23,036
+12,373
+116% +$58.3K
RRD
1720
DELISTED
RR Donnelley & Sons Co.
RRD
$119K ﹤0.01%
+12,837
New +$117K
NBRV
1721
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$118K ﹤0.01%
+79
New +$125K
RARX
1722
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$118K ﹤0.01%
+13,935
New +$171K
TRUE
1723
DELISTED
TrueCar
TRUE
$117K ﹤0.01%
+10,445
New +$138K
ECYT
1724
DELISTED
Endocyte, Inc. Common Stock
ECYT
$110K ﹤0.01%
+25,795
New +$123K
FTD
1725
DELISTED
FTD Companies, Inc. Common Stock
FTD
$109K ﹤0.01%
+15,192
New +$141K

Similar funds

ProShare Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, ProShare Advisors held 1,820 positions worth $14.4B, up 32% from $10.9B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

ProShare Advisors deployed $2.81B of net new capital in Q4 2017, opening 468 new positions and adding to 1,221 existing holdings. Its largest new stake was ASML: 31,220 shares worth $5.43M.

By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 14% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was VF Corp, an estimated $4.38M trimmed.

  • ProShare Advisors's largest Q4 2017 buy was ASML: 31,220 shares worth $5.43M.
  • ProShare Advisors added most to Apple in Q4 2017, an estimated $160M increase.
  • ProShare Advisors's biggest Q4 2017 reduction was VF Corp, cutting an estimated $4.38M.
  • ProShare Advisors fully exited CR Bard Inc. in Q4 2017, selling an estimated $62.3M.
  • ProShare Advisors's ten largest holdings make up 18% of its $14.4B portfolio in Q4 2017.
  • ProShare Advisors opened 468 new positions and closed 21 in Q4 2017.
  • ProShare Advisors's portfolio value rose 32% quarter-over-quarter to $14.4B.

Based on ProShare Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.